Skip to main content

San Antonio Breast Cancer Symposium, presented by UT Health San Antonio and the American Association for Cancer Research (AACR). More than 10,000 cancer researchers, clinicians and patient advocates from across the globe are expected to attend this year’s San Antonio Breast Cancer Symposium, Dec. 10-13.

The meeting will feature presentations by several University of North Carolina-Chapel Hill and UNC Lineberger Comprehensive Cancer Center faculty members and trainees.


Wednesday, Dec. 11

Oral Presentation

 2 – 3 p.m. CT | Stars at Night 1-2

Translational Controversies: How to Define Triple Negative Breast Cancer

Presenter: Charles Perou, PhD

 

Poster Presentation

12:30 – 2 p.m. CT  |  Halls 2-3

Poster Session 2

P1-02-24: Leveraging bulk and single-cell RNA sequencing to identify features predicting response and survival to abemaciclib in six mouse models of breast cancer

Presenter: Yash Agrawal, MD

 

P1-11-25: Real-World Data on Adjuvant Abemaciclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: A Retrospective Study

Presenter: Paola Zagami, MD

 

5:30 – 7:30 p.m. CT  |  Halls 2-3

Poster Session 2

P2-03-15: Identifying pre-habilitation targets for the mitigation of long-term side effects of chemotherapy in patients with early breast cancer

Presenter: Lyndsay Cooper


Thursday, Dec. 12

Poster Presentation

 7 – 8:30 a.m. CT | Hemisfair Ballroom 1-2

 Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers

 Moderator: Lisa Carey, MD, ScM, FASCO

 

7 – 8:30 a.m. CT | Stars at Night 3-4

Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies

Moderator: Charles Perou, PhD

 

7:30 –7:45 a.m. CT Evaluating Minimal Residual Disease

Discussant: Yara Abdou, MD

 

Oral Presentation

9 – 11:45 am. CT  |  Hall 1

GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for “Good Risk” Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial

Presenter: Jean Wright, MD, FASCO

 

Poster Presentation

12:30 – 2 p.m. CT | Halls 2-3

Poster Session 3

P3-06-14: Evaluating “Spinning Science” A Patient-Led Health Literacy Educational Program for People Living with Metastatic Breast Cancer

Presenter: Mya Roberson, PhD, MSPH

 

Clinical Controversies

2 – 3 p.m. CT  |  Stars at Night 1-2 

Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy

Presenter: Jean Wright, MD, FASCO

 

Educational Session

3:30 – 5:15 p.m. CT  |  Stars at Night 3-4

Digital Tools for Clinical Practice

Presenter: Emily Ray, MD, MPH


Friday, Dec. 13

Poster Presentation

7 – 8:30 a.m. CT  |  Hemisfair Ballroom 3

Session 10: Addressing Racial Disparities in Breast Cancer Outcomes

Moderator: Yara Abdou, MD

 

7 – 8:30 a.m. CT  |  Room 221ABC

Session 12: Immunobiology Impact on Therapeutic Efficacy

PS12-05: PARP7 inhibition combined with radiotherapy overcomes ICI resistance in breast cancer

Presenter: Lynn Lerner

 

Oral Presentation

9 – 11:45 a.m. CT | Hall 1

General Session 3

GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer

Presenter: Brooke Felsheim

 

Poster Presentation

12:30 – 2 p.m. CT  |  Halls 2-3

Poster Session 5

P5-02-08: Assessing Medical Mistrust among Black Adults with and without a Family History of Breast Cancer

Presenter: Mya Roberson, PhD, MSPH

 

P5-12-21: The utility of antiestrogen therapy in early-stage, pure mucinous carcinomas of the breast

Presenter: Lyndsay Cooper